References
- Health resources - pharmaceutical spending - OECD data [Internet]. theOECD. [cited 2020 Aug 18]. Available from: http://data.oecd.org/healthres/pharmaceutical-spending.htm
- IQVIA. The global use of medicine in 2019 and outlook to 2023: forecasts and areas to watch. Institute Report. 2019 Jan 29.
- OECD. Health at a glance 2019: OECD indicators. Paris: OECD Publishing; 2019.
- Hernandez I, San-Juan-Rodriguez A, Good CB, et al. Changes in list prices, net prices, and discounts for branded drugs in the US, 2007–2018. JAMA. 2020;323(9):854–862.
- Alpern JD, Shahriar AA, Xi M, et al. Characteristics and price increases among sole-source, off-patent drugs in the United States, 2008 to 2018. JAMA Network Open. 2020;3(8):e2013595–e2013595. .
- Kakkar AK, Shafiq N, Malhotra S. Ensuring access to ‘access’ antibiotics: an imminent consideration for sustainable antimicrobial stewardship in the developing world. Infect Dis. 2019;51(5):395–398.
- WHO. 2020. WHO guideline on country pharmaceutical pricing policies. [cited 2020 Dec 28]. Available at: https://www.who.int/publications/i/item/9789240011878
- Vernon JA. Examining the link between price regulation and pharmaceutical R&D investment. Health Econ. 2005;14(1):1–16.
- Eger S, Mahlich JC Pharmaceutical regulation in Europe and its impact on corporate R&D. Health Econ Rev [Internet]. 2014 Oct 3 [cited 2020 Aug 20];4. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4502069/
- “Examination of international drug pricing policies in selected countries shows prevalent government control over pricing and restrictions on access.” Galen Institute, March 2019.
- European pharmaceutical price regulation, firm profitability, and R&D spending Joseph H. Golec and John A. Vernon NBER working paper no. 12676 november 2006.
- Danzon PM, Chao L. Does regulation drive out competition in pharmaceutical markets? J Law Econ. 2000;43(2):311–358.
- Sood N, De Vries H, Gutierrez I, et al. The effect of regulation on pharmaceutical revenues: experience in nineteen countries. Health Aff Proj Hope [Internet]. 2009 [cited 2020 Aug 19];28(1). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3829766/
- Dean EB, 2019. “Who Benefits from pharmaceutical price controls? Evidence from India .” CGD Working Paper 509. Washington, DC: Center for Global Development. [cited 2020 Aug 25]. Available from: https://www.cgdev.org/publication/who-benefits-pharmaceutical-pricecontrols-evidence-india
- Khanijo S, Kakkar AK, Kumar R, et al. Impact of pharmaceutical price controls on the cost of cardiovascular drugs: does essentiality matter? Expert Rev Clin Pharmacol. 2020;13(7):797–806.
- FDA approves more generic drugs, but competition still lags [Internet]. [cited 2020 Aug 21]. Available from: https://pew.org/2GFjs2Y
- Research C for DE and. list of off-patent, off-exclusivity drugs without an approved generic. FDA [Internet]. 2020 Jun 18 [cited 2020 Aug 21]; Available from: https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/list-patent-exclusivity-drugs-without-approved-generic
- Jung EH, Sarpatwari A, Kesselheim AS, et al. FDA and EMA Biosimilar Approvals. J Gen Intern Med. 2020 Jun;35(6):1908–1910.
- Cohen H, Beydoun D, Chien D, et al. Awareness, knowledge, and perceptions of biosimilars among specialty physicians. Adv Ther. 2017;33(12):2160–2172. .
- Kakkar AK. Patent cliff mitigation strategies: giving new life to blockbusters. Expert Opin Ther Pat. 2015;25(12):1353–1359.
- Schuhmacher A, Gassmann O, Changing R&D HM. Models in research-based pharmaceutical companies. J Transl Med. 2016;14(1):105.
- Lamberti MJ, Getz K Profiles of new approaches to improving the efficiency and performance of pharmaceutical drug development. 2015.
- Siddiqui M, Rajkumar SV. The high cost of cancer drugs and what we can do about it. Mayo Clin Proc. 2012;87(10):935–943.